Therapeutic choices in the treatment of acute community-acquired bacterial rhinosinusitis

Am J Rhinol. 2006 Nov-Dec;20(6):662-6. doi: 10.2500/ajr.2006.20.2954.

Abstract

Background: Acute bacterial rhinosinusitis (ABRS) is a common medical problem affecting a large percentage of the population. The disease will most often follow a viral upper respiratory tract infection.

Methods: Appropriately diagnosed, ABRS is best treated with antibiotics, but other medications may play a role in some circumstances. Increasing antibiotic resistance to the common bacteria causing ABRS has occurred in the past 20 years, driven largely by inappropriate or unnecessary antibiotic use.

Results: There are many antibiotics available that may be used for the treatment of ABRS. The selection of the best antibiotic option is determined by evaluating a number of factors, with the potential antibiotic resistance being an important consideration.

Conclusion: This article reviews current recommendations for the antibiotic treatment of ABRS.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute Disease
  • Anti-Bacterial Agents / therapeutic use*
  • Community-Acquired Infections / drug therapy*
  • Glucocorticoids / therapeutic use*
  • Humans
  • Rhinitis / complications
  • Rhinitis / drug therapy*
  • Sinusitis / complications
  • Sinusitis / drug therapy*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Glucocorticoids